JD Health International, Inc. (6618) AI Stock Analysis

• Market Cap: HK$206.50B
• Dividend Yield: N/A
• Average Volume (3M): 11.34M
• Price to Earnings (P/E): 39.9
• Beta (1Y): 1.49
• Revenue Growth: 18.56%
• EPS Growth: 79.54%
• Country: HK
• Employees: 3,564
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.89
• Shares Outstanding: 3,201,475,000
• 10 Day Avg. Volume: 7,787,970
• 30 Day Avg. Volume: 11,337,884
• PEG Ratio: 0.21
• Price to Book (P/B): 1.51
• Price to Sales (P/S): 1.43
• P/FCF Ratio: 19.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$71.73
• Price Target Upside: 11.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 76 Outperform
• Price Target: HK$75.00 ▲(16.28% Upside)

JD Health International, Inc. demonstrates strong financial performance and positive earnings call sentiment, driving a high overall score. Technical indicators show strong momentum but suggest caution due to overbought conditions. The high P/E ratio indicates potential overvaluation, slightly tempering the overall score.

JD Health International, Inc. Business Overview & Revenue Model

Company Description

JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online healthcare services, online consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, it offers access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.

How the Company Makes Money

JD Health International, Inc. generates revenue primarily through its online pharmacy platform, which sells a vast array of pharmaceutical and healthcare products directly to consumers. The company also earns income by offering online medical consultation services, where users can pay for virtual consultations with healthcare professionals. Additionally, JD Health leverages its platform to offer health management services and personalized wellness programs, contributing to its revenue streams. Strategic partnerships with hospitals, clinics, and pharmaceutical companies further enhance its service offerings and expand its customer base, driving additional revenue growth.

JD Health International, Inc. Financial Statement Overview

Summary

JD Health International, Inc. presents a compelling financial profile with strong revenue growth, improved profitability, and a stable balance sheet. The company has effectively managed its debt levels, ensuring financial stability. Cash flow generation remains robust, supporting its operations and growth initiatives.

Income Statement

JD Health International, Inc. has demonstrated strong revenue growth over the years, with a notable increase from 2019 to 2024. Gross profit margins have remained healthy, reflecting efficient cost management. The net profit margin has improved significantly, turning from losses in earlier years to profitable outcomes in recent periods, showcasing strong profitability. EBIT and EBITDA margins have shown positive trends, indicating enhanced operational efficiency.

Balance Sheet

The company's balance sheet is robust, characterized by a high equity ratio, which indicates strong financial stability and low reliance on debt. The debt-to-equity ratio is low, suggesting prudent financial management and reduced financial risk. Return on equity has improved significantly, reflecting better utilization of shareholders' funds.

Cash Flow

JD Health International exhibits a solid cash flow position, with consistent operating cash flow generation. Free cash flow growth has been positive, indicating strong cash generation capabilities. The operating cash flow to net income ratio is healthy, underscoring efficient cash conversion. However, a slight decline in operating cash flow compared to the previous year is a point of concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.11B	58.16B	53.53B	46.74B	30.68B	19.38B
Gross Profit	15.50B	13.31B	11.87B	9.89B	7.20B	4.92B
EBITDA	2.49B	1.31B	2.93B	-60.93M	-1.37B	364.50M
Net Income	4.72B	4.16B	2.14B	380.11M	-1.07B	-17.23B
Balance Sheet
Total Assets	78.46B	71.27B	64.29B	61.28B	48.00B	43.99B
Cash, Cash Equivalents and Short-Term Investments	49.31B	51.24B	41.22B	47.67B	41.99B	40.30B
Total Debt	429.69M	258.39M	214.75M	199.41M	201.27M	89.98M
Total Liabilities	20.48B	16.03B	14.92B	16.49B	8.15B	4.74B
Stockholders Equity	57.97B	55.23B	49.36B	44.78B	39.85B	39.25B
Cash Flow
Free Cash Flow	8.32B	4.29B	4.54B	5.86B	2.93B	3.68B
Operating Cash Flow	8.35B	4.33B	4.60B	5.91B	3.43B	3.70B
Investing Cash Flow	7.96B	3.15B	-8.02B	-4.24B	-17.75B	-7.84B
Financing Cash Flow	-54.11M	-45.61M	-117.20M	-925.45M	-163.65M	32.03B

JD Health International, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 64.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6618, the sentiment is Positive. The current price of 64.5 is below the 20-day moving average (MA) of 66.68, above the 50-day MA of 60.37, and above the 200-day MA of 41.77, indicating a bullish trend. The MACD of 1.75 indicates Positive momentum. The RSI at 55.44 is Neutral, neither overbought nor oversold. The STOCH value of 31.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6618.

JD Health International, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6618	76 Outperform	HK$206.50B	39.93	8.52%	―	18.56%	79.54%
3689	71 Outperform	HK$662.10M	8.02	1.07%	8.08%	0.47%	50.46%
1526	66 Neutral	HK$1.62B	5.59	22.09%	4.41%	-3.56%	-17.45%
6078	65 Neutral	HK$8.45B	17.20	8.99%	―	-13.92%	-36.32%
2273	65 Neutral	HK$7.18B	19.29	12.91%	2.50%	16.41%	32.97%
1951	60 Neutral	HK$7.74B	-7.43	2.76%	2.11%	-8.56%	-403.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

JD Health International, Inc. Corporate Events

JD Health Reports Strong Growth in H1 2025, Driven by AI and Healthcare Innovations

JD Health International, Inc. announced its interim results for the first half of 2025, reporting significant financial growth with a 24.5% increase in revenue to RMB35.3 billion and a 27.4% rise in profit to RMB2.59 billion. The company has improved its healthcare offerings and advanced AI-enhanced service models, reinforcing its leading position in the healthcare market and addressing the growing demand for high-quality healthcare services. The company’s strategic focus on AI and health consumption aligns with China’s policies promoting high-quality healthcare development, further solidifying its market position.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$56.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health International Schedules Board Meeting to Approve Interim Results

JD Health International Inc. has announced a board meeting scheduled for August 14, 2025, to approve and publish its unaudited interim results for the first half of 2025. The meeting will also consider the recommendation for an interim dividend. The company will host a conference call on the same day to discuss these results, indicating a proactive approach in engaging with stakeholders and maintaining transparency in its financial operations.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health Grants Over 800,000 Award Shares to Employees

JD Health International, Inc. announced the grant of 834,433 Award Shares to its employees under the Post-IPO Share Award Scheme, representing approximately 0.03% of the total issued shares. The shares will vest over various periods ranging from 0.25 to 4 years, with no performance targets attached. This move aims to incentivize employees and align their interests with the company’s growth, potentially enhancing employee retention and satisfaction.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.